United States Chronic Obstructive Pulmonary Disease Market Size & Forecast 2025–2033

The United States Chronic Obstructive Pulmonary Disease (COPD) Market is expanding at a steady pace, driven by rising disease prevalence, an aging population, and advancements in respiratory treatment technologies. According to Renub Research, the U.S. COPD market is projected to rise from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, reflecting a CAGR of 2.42% during 2025–2033.

COPD—which includes chronic bronchitis and emphysema—remains one of the country’s leading causes of death. As the U.S. population grows older and exposure to risk factors like smoking, industrial pollutants, and poor air quality persists, demand for improved therapies, advanced inhalers, digital respiratory tools, and comprehensive pulmonary rehabilitation continues to increase.

This report-style editorial explores the state of the COPD market in the U.S., the forces driving growth, industry innovations, state-level dynamics, and the challenges that must be addressed to improve long-term patient outcomes.

United States COPD Industry Overview

The United States continues to face a rising burden of COPD due to demographic shifts, environmental factors, and lifestyle-related risks. Millions of Americans live with COPD, and many remain undiagnosed until the disease reaches a moderate or severe stage. The Centers for Disease Control and Prevention (CDC) estimates that COPD-related mortality and morbidity remain persistently high, especially in regions with elevated smoking rates and limited access to healthcare.

The U.S. COPD market is heavily shaped by pharmaceutical interventions. Bronchodilators, corticosteroids, and combination inhalers, including LAMAs, LABAs, and triple therapy options, form the backbone of treatment. However, innovation is accelerating, with companies investing in targeted biologics, next-generation inhalation devices, long-acting therapies, and digital health solutions.

Recent landmark approvals are reshaping care for severe COPD patients:

OHTUVAYRE (June 2024), a dual PDE3/4 inhibitor, approved as maintenance therapy

DUPIXENT (September 2024) approved for COPD with eosinophilic phenotype

NUCALA (May 2025) extended approval for eosinophilic COPD

Beyond medications, oxygen therapy, non-invasive ventilation, and pulmonary rehabilitation remain essential components of chronic care. Telehealth and digital respiratory devices are improving adherence, while remote monitoring platforms enable clinicians to track symptoms and intervene early.

Despite these advancements, challenges persist: COPD is still diagnosed late, treatment costs remain high, and disparities in care access disproportionately affect low-income and rural communities. As policy and clinical innovations expand, the market is expected to continue growing steadily, supported by technology adoption, aging demographics, and heightened investment in respiratory health.

Key Factors Driving U.S. COPD Market Growth

1. Population Aging and Rising COPD Prevalence

The most significant factor fueling market growth is the rapid expansion of the 65+ population. The U.S. Census Bureau projects that the senior population will nearly double by 2060, dramatically increasing the pool of individuals at risk for COPD. Lung function naturally decreases with age, making older adults more vulnerable to respiratory diseases.

In addition, ongoing exposure to:

Cigarette smoke

Poor indoor and outdoor air quality

Industrial pollutants

Dust and chemical fumes in occupational settings

continues to contribute to rising COPD cases. Improved screening tools, better public awareness campaigns, and increased primary care involvement are bringing more patients into the diagnostic pipeline—supporting rising demand for long-term treatment options.

2. Advancements in Drug Innovation and Inhalation Therapy

Pharmaceutical companies are moving rapidly to deliver more effective, patient-friendly COPD therapies. The major trends include:

➤ Triple Therapy Inhalers

These inhalers, combining LAMA + LABA + ICS, help reduce exacerbations and improve airflow.

➤ Next-Generation Inhaler Designs

Innovations include:

Breath-actuated inhalers

Soft-mist inhalers

Digital-connected inhalers

These devices improve ease of use, especially for elderly patients, and offer better dosing accuracy.

➤ Targeted Biologics

For patients with eosinophilic or severe COPD, biologics represent a breakthrough that may significantly reduce flare-ups.

➤ Long-Acting Bronchodilators

These enhance patient compliance and help maintain stable lung function.

As companies continue investing in R&D, the U.S. COPD market is benefiting from improved therapeutic outcomes, reduced hospitalization rates, and enhanced patient quality of life.

3. Expansion of Home-Based Respiratory Care and Telehealth

After the pandemic accelerated telemedicine adoption, respiratory care has seen a major transformation. Digital solutions are increasingly used for disease monitoring and intervention.

Key technologies reshaping COPD care include:

Digital spirometry for home lung function tests

Remote oxygen monitoring

Virtual pulmonary rehabilitation sessions

Apps that track symptoms and inhaler use

Telehealth has become particularly valuable for:

Rural communities

Mobility-restricted older adults

Patients requiring frequent monitoring

As value-based care models continue to expand, remote COPD management is emerging as a cost-effective and patient-centric approach, further boosting market growth.

Challenges in the U.S. COPD Market

1. Underreporting of Cases and Delayed Diagnosis

COPD often progresses silently. Symptoms like:

Shortness of breath

Persistent cough

Fatigue

are frequently attributed to aging or mild respiratory infections. Many patients do not seek care until COPD is advanced, reducing treatment efficacy.

Rural communities face additional challenges:

Limited access to pulmonologists

Lack of diagnostic equipment

Reduced awareness

Improving early screening and standardizing diagnostic guidelines remain essential to reducing the national COPD burden.

2. High Treatment Costs and Healthcare Inequities

The long-term nature of COPD care makes treatment expensive. Patients must manage:

Frequent physician visits

Costly inhalers or biologics

Pulmonary rehabilitation

Oxygen therapy

While Medicare and Medicaid help millions, barriers remain:

High copays

Restricted drug formularies

Limited coverage for pulmonary rehabilitation

Geographic disparities affecting specialist access

These inequalities contribute to higher hospitalizations and poorer long-term outcomes in vulnerable populations.

United States COPD Market Overview by Key States

California

California holds a strong position in the COPD market due to its large aging demographic and diverse environmental conditions. High air pollution in the Central Valley and parts of Southern California continues to drive COPD incidence. Although the state benefits from advanced healthcare facilities and rising telehealth adoption, disparities persist in rural areas.

Market growth will be driven by:

Early screening programs

Environmental health regulations

Technological adoption in respiratory care

Texas

Texas represents one of the largest COPD markets due to its vast population and notable rural-versus-urban healthcare divide. While cities like Houston and Dallas have advanced pulmonary centers, rural regions face limited specialist availability and delayed diagnoses.

Key drivers include:

Expansion of telemedicine

Rising industrial exposure

Increasing adoption of personalized COPD therapies

Texas is expected to see steady COPD market growth through 2033.

New York

New York remains a critical market, supported by a dense population and a robust healthcare ecosystem. Advanced pulmonary centers in New York City offer cutting-edge therapies, including triple combination inhalers and innovative rehabilitation programs.

Market challenges include:

High pollution in certain boroughs

Persistent disparities in low-income urban neighborhoods

Specialist shortages in rural upstate regions

As mobile clinics, telehealth, and targeted public health campaigns expand, New York’s COPD management landscape is set to improve substantially.

Market Segmentations

By Type

Chronic Bronchitis

Emphysema

By Treatment Types

Drugs

Oxygen Therapy

Surgery

Others

By Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By States

California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, New Jersey, Washington, North Carolina, Massachusetts, Virginia, Michigan, Maryland, Colorado, Tennessee, Indiana, Arizona, Minnesota, Wisconsin, Missouri, Connecticut, South Carolina, Oregon, Louisiana, Alabama, Kentucky, and Rest of U.S.

Key Companies Covered

AstraZeneca

Pfizer Inc.

GlaxoSmithKline plc

Novartis AG

Astellas Pharma Inc.

Abbott Laboratories

Boehringer Ingelheim International GmbH

Almirall

Each company is evaluated on:

✔ Overview

✔ Key Personnel

✔ Recent Developments

✔ SWOT Analysis

✔ Revenue Analysis

Final Thoughts

The United States COPD market is entering a transformative decade. With the population aging and environmental risk factors persisting, COPD prevalence will continue rising. Yet innovations in biologics, inhaler technology, telehealth, and digital disease management are reshaping the landscape of respiratory care.

While challenges such as high treatment costs, diagnostic delays, and unequal healthcare access remain, strategic investments and policy reforms will be pivotal in ensuring that millions of COPD patients receive timely and effective treatment.

As the U.S. moves toward a more personalized, tech-enabled healthcare system, the COPD market will continue advancing—unlocking improved outcomes, better quality of life, and more efficient long-term management for patients across the country.